2 newer multiple myeloma drugs fall short in bid for wider market

2 newer multiple myeloma drugs fall short in bid for wider market

Source: 
BioPharma Dive
snippet: 

Two newer drugs for multiple myeloma failed to improve on a commonly used treatment regimen in separate late-stage studies of newly diagnosed patients, showcasing the difficulty in improving on Celgene's top-seller Revlimid in early disease settings.